Name | Number of supported studies | Average coverage | |
---|---|---|---|
macrophage | 29 studies | 49% ± 23% | |
conventional dendritic cell | 26 studies | 43% ± 17% | |
classical monocyte | 25 studies | 56% ± 23% | |
non-classical monocyte | 24 studies | 70% ± 22% | |
monocyte | 20 studies | 49% ± 20% | |
dendritic cell | 19 studies | 46% ± 25% | |
B cell | 10 studies | 30% ± 16% | |
myeloid cell | 10 studies | 41% ± 17% | |
alveolar macrophage | 6 studies | 45% ± 25% | |
mononuclear phagocyte | 6 studies | 44% ± 21% | |
memory B cell | 5 studies | 26% ± 8% | |
intermediate monocyte | 5 studies | 62% ± 22% | |
neutrophil | 4 studies | 37% ± 24% | |
monocyte-derived dendritic cell | 4 studies | 76% ± 24% | |
microglial cell | 4 studies | 30% ± 11% | |
tissue-resident macrophage | 3 studies | 49% ± 31% | |
leukocyte | 3 studies | 24% ± 4% | |
plasmablast | 3 studies | 60% ± 5% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 7 studies | 26% ± 5% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 100% | 20785.02 | 577 / 578 | 35% | 0.71 | 402 / 1155 |
kidney | 100% | 3950.48 | 89 / 89 | 32% | 0.75 | 288 / 901 |
stomach | 88% | 3319.25 | 317 / 359 | 19% | 0.32 | 54 / 286 |
adrenal gland | 98% | 6371.50 | 254 / 258 | 8% | 0.14 | 18 / 230 |
peripheral blood | 100% | 48698.35 | 929 / 929 | 0% | 0 | 0 / 0 |
spleen | 100% | 19082.98 | 241 / 241 | 0% | 0 | 0 / 0 |
pancreas | 66% | 1651.02 | 218 / 328 | 31% | 0.55 | 56 / 178 |
breast | 85% | 2928.10 | 391 / 459 | 11% | 0.17 | 119 / 1118 |
adipose | 91% | 5556.10 | 1099 / 1204 | 0% | 0 | 0 / 0 |
liver | 81% | 3234.80 | 183 / 226 | 6% | 0.12 | 26 / 406 |
thymus | 81% | 2029.88 | 531 / 653 | 5% | 0.08 | 30 / 605 |
intestine | 68% | 2950.36 | 656 / 966 | 17% | 0.26 | 88 / 527 |
lymph node | 0% | 0 | 0 / 0 | 83% | 2.08 | 24 / 29 |
bladder | 57% | 2232.52 | 12 / 21 | 20% | 0.34 | 100 / 504 |
skin | 63% | 1312.70 | 1147 / 1809 | 13% | 0.21 | 59 / 472 |
esophagus | 42% | 1049.95 | 614 / 1445 | 17% | 0.28 | 32 / 183 |
prostate | 51% | 1416.37 | 125 / 245 | 4% | 0.07 | 22 / 502 |
blood vessel | 51% | 2427.03 | 677 / 1335 | 0% | 0 | 0 / 0 |
uterus | 19% | 412.99 | 33 / 170 | 15% | 0.22 | 71 / 459 |
ovary | 16% | 336.49 | 29 / 180 | 15% | 0.26 | 65 / 430 |
heart | 28% | 671.09 | 237 / 861 | 0% | 0 | 0 / 0 |
brain | 11% | 296.91 | 292 / 2642 | 9% | 0.17 | 62 / 705 |
tonsil | 0% | 0 | 0 / 0 | 16% | 0.23 | 7 / 45 |
muscle | 1% | 23.27 | 10 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0019886 | Biological process | antigen processing and presentation of exogenous peptide antigen via MHC class II |
GO_0048147 | Biological process | negative regulation of fibroblast proliferation |
GO_0050821 | Biological process | protein stabilization |
GO_0042590 | Biological process | antigen processing and presentation of exogenous peptide antigen via MHC class I |
GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
GO_0030054 | Cellular component | cell junction |
GO_0043202 | Cellular component | lysosomal lumen |
GO_0005764 | Cellular component | lysosome |
GO_0005829 | Cellular component | cytosol |
GO_0005576 | Cellular component | extracellular region |
GO_0016671 | Molecular function | oxidoreductase activity, acting on a sulfur group of donors, disulfide as acceptor |
GO_0016667 | Molecular function | oxidoreductase activity, acting on a sulfur group of donors |
GO_0005515 | Molecular function | protein binding |
Gene name | IFI30 |
Protein name | Interferon gamma-inducible protein 30 Gamma-interferon-inducible lysosomal thiol reductase (EC 1.8.-.-) (Gamma-interferon-inducible protein IP-30) (Legumaturain) Gamma-interferon-inducible lysosomal thiol reductase (EC 1.8.-.-) (Gamma-interferon-inducible protein IP-30) |
Synonyms | IP30 GILT |
Description | FUNCTION: Lysosomal thiol reductase that can reduce protein disulfide bonds. May facilitate the complete unfolding of proteins destined for lysosomal degradation. Plays an important role in antigen processing. Facilitates the generation of MHC class II-restricted epitodes from disulfide bond-containing antigen by the endocytic reduction of disulfide bonds (By similarity). Facilitates also MHC class I-restricted recognition of exogenous antigens containing disulfide bonds by CD8+ T-cells or crosspresentation (By similarity). . FUNCTION: Lysosomal thiol reductase that can reduce protein disulfide bonds. Facilitates the complete unfolding of proteins destined for lysosomal degradation. Plays an important role in antigen processing. . |
Accessions | Q96P99 ENST00000597802.2 P13284 M0QZG3 ENST00000407280.4 |